Vera Therapeutics
VERA
175 hedge funds and large institutions have $1.89B invested in Vera Therapeutics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 67 increasing their positions, 48 reducing their positions, and 32 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
40% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 48
26% more capital invested
Capital invested by funds: $1.51B → $1.89B (+$385M)
1.76% more ownership
Funds ownership: 100.19% → 101.95% (+1.8%)
2% more funds holding
Funds holding: 172 → 175 (+3)
9% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 32
48% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $5.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.3M |
| 3 |
TLP
Tri Locum Partners
New York
|
+$18M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$15.4M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$54.1M |
| 2 |
Morgan Stanley
New York
|
-$45.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$43.3M |
| 4 |
CC
Commodore Capital
New York
|
-$18.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.8M |
VERA Hedge Fund Activity: Q3 2025 in Review
175 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2025, worth a combined $1.89B — up 26% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new VERA positions and 32 closed out — a net gain of 3 holders — while 67 added to existing stakes and 48 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $29.4M. The largest seller was Vestal Point Capital, cutting an estimated $54.1M.
- 175 institutional investors held Vera Therapeutics (VERA) as of Q3 2025, up from 172 in Q2 2025.
- Funds reported $1.89B of Vera Therapeutics stock for Q3 2025, up 26% quarter-over-quarter.
- 35 funds opened new Vera Therapeutics positions in Q3 2025 and 32 closed out, a net change of +3 holders.
- The largest Vera Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $29.4M added.
- The largest Vera Therapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $54.1M sold.
Based on aggregated 13F filings for Q3 2025.